Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy M Lin

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Current Opinion in Oncology|April 7, 2007
Prostate cancer update: 2006Amy M Lin, Eric J Small
Current Opinion in Supportive and Palliative Care|August 8, 2008
Management of hormone refractory prostate cancerAmy M Lin, Eric J Small
Current Opinion in Oncology|April 9, 2008
Prostate cancer update: 2007Amy M Lin, Eric J Small
Urologic Oncology|May 9, 2006
Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationaleCharles J Ryan, Amy M Lin, Eric J Small
Critical Reviews in Oncology/Hematology|December 13, 2006
Intermittent chemotherapy for metastatic hormone refractory prostate cancerAmy M Lin, Charles J Ryan, Eric J Small
BJU International|April 29, 2006
Clinical trials in patients with biochemically relapsed prostate cancerAmy M Lin, Brian I Rini, Eric J Small
Urologic Oncology|September 12, 2006
Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cellsAmy M Lin, Robert M Hershberg, Eric J Small
Stroke|December 25, 2018
Less Than Ideal: Trends in Cardiovascular Health Among US Stroke SurvivorsAmy M Lin, Michelle P Lin, Daniela Markovic, et al.
Journal of Computer Assisted Tomography|January 20, 2011
Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequencesHenry Chow, Adam Jung, Jason Talbott, et al.
The Oncologist|March 19, 2017
A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate CancerXiao X Wei, Andrew C Hsieh, Won Kim, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Current Opinion in Oncology|April 7, 2007
Prostate cancer update: 2006Amy M Lin, Eric J Small
Current Opinion in Supportive and Palliative Care|August 8, 2008
Management of hormone refractory prostate cancerAmy M Lin, Eric J Small
Current Opinion in Oncology|April 9, 2008
Prostate cancer update: 2007Amy M Lin, Eric J Small
Urologic Oncology|May 9, 2006
Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationaleCharles J Ryan, Amy M Lin, Eric J Small
Critical Reviews in Oncology/Hematology|December 13, 2006
Intermittent chemotherapy for metastatic hormone refractory prostate cancerAmy M Lin, Charles J Ryan, Eric J Small
BJU International|April 29, 2006
Clinical trials in patients with biochemically relapsed prostate cancerAmy M Lin, Brian I Rini, Eric J Small
Urologic Oncology|September 12, 2006
Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cellsAmy M Lin, Robert M Hershberg, Eric J Small
Stroke|December 25, 2018
Less Than Ideal: Trends in Cardiovascular Health Among US Stroke SurvivorsAmy M Lin, Michelle P Lin, Daniela Markovic, et al.
Journal of Computer Assisted Tomography|January 20, 2011
Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequencesHenry Chow, Adam Jung, Jason Talbott, et al.
The Oncologist|March 19, 2017
A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate CancerXiao X Wei, Andrew C Hsieh, Won Kim, et al.
Pageof 3